Comparison of the efficacy of simvastatin and standard fibrate therapy in the treatment of primary hypercholesterolemia and combined hyperlipidemia

Clinical Cardiology
Eric BruckertF Baigts

Abstract

Five multicenter, randomized, double-blind, placebo-controlled studies were conducted in France to compare the efficacy and safety of once-daily simvastatin treatment (10-40 mg/day) with conventional therapy with gemfibrozil 900 mg/day, ciprofibrate 100 mg/day, bezafibrate 400 mg/day, and fenofibrate 300 or 400 mg/day in a total of 800 patients with hypercholesterolemia. Simvastatin was associated with statistically significantly greater (p < or = 0.01) mean percent reductions in plasma low-density lipoprotein (LDL) cholesterol compared with each of the five fibrate regimens, even when administered at its recommended starting dose of 10 mg/day. Furthermore, approximately 90% of patients treated once daily with simvastatin experienced an at least 20% decrease in plasma LDL cholesterol compared with only 36 to 68% of patients treated with the individual fibrate agents (p < or = 0.05). The effectiveness of simvastatin in reducing LDL cholesterol did not differ as a function of the baseline plasma concentrations of total cholesterol or triglycerides. In contrast, the effectiveness of fibrate therapy in lowering plasma LDL cholesterol levels was significantly diminished (p < or = 0.05) among patients with triglyceride concentrations...Continue Reading

References

Jan 1, 1991·Arteriosclerosis and Thrombosis : a Journal of Vascular Biology·M A Austin
Dec 19, 1990·JAMA : the Journal of the American Medical Association·J P KaneR J Havel
Jun 1, 1990·Archives of Internal Medicine·G L Vega, S M Grundy
Oct 1, 1989·European Journal of Clinical Investigation·M S WeintraubJ L Breslow
Mar 15, 1989·The American Journal of Cardiology·D A PietroT J Cook
Nov 1, 1989·Journal of Internal Medicine·K Ytre-Arne, A Nordøy
May 11, 1989·The New England Journal of Medicine·J D Brunzell, M A Austin
Aug 5, 1988·JAMA : the Journal of the American Medical Association·V ManninenP Koskinen
Jul 1, 1988·Annals of Internal Medicine·C EastS M Grundy
Jun 19, 1987·JAMA : the Journal of the American Medical Association·D H BlankenhornL Cashin-Hemphill
Apr 24, 1987·JAMA : the Journal of the American Medical Association·K M AndersonD Levy
Aug 1, 1986·American Heart Journal·W P Castelli
Apr 1, 1993·La Revue de médecine interne·J M LecerfB Devulder

❮ Previous
Next ❯

Citations

Aug 7, 2002·Pharmacology & Therapeutics·Helen VosperColin N A Palmer
Jul 28, 2007·International Journal of Clinical Practice·E Bruckert, B Hansel
Jan 4, 2003·Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan·Toru HayakawaNobuo Inotsume
Aug 24, 2010·Vascular Health and Risk Management·Elisavet MoutzouriHaralampos J Milionis
Apr 9, 2008·European Journal of Internal Medicine·Inbal AvisarEfrat Wolfovitz
Aug 18, 2000·The American Journal of Cardiology·E SteinM Mercuri
Oct 26, 1999·The Annals of Pharmacotherapy·D R Guay
Dec 13, 2003·European Journal of Cardiovascular Prevention and Rehabilitation : Official Journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology·Philippe AutierAndré-Robert Grivegnée
Dec 17, 2009·Journal of General Internal Medicine·Neelam A VashiBradley Sabin

❮ Previous
Next ❯

Related Concepts

Related Feeds

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.

Related Papers

European Journal of Cardiovascular Prevention and Rehabilitation : Official Journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology
Mukesh SinghJawad M Khan
Expert Opinion on Investigational Drugs
Eric Bruckert
© 2021 Meta ULC. All rights reserved